Cyclacel Tangible Book Value Per Share from 2010 to 2024

CYCC Stock  USD 2.00  0.12  5.66%   
Cyclacel Pharmaceuticals' Tangible Book Value Per Share is increasing over the years with slightly volatile fluctuation. Overall, Tangible Book Value Per Share is expected to go to 0.75 this year. During the period from 2010 to 2024 Cyclacel Pharmaceuticals Tangible Book Value Per Share annual values regression line had coefficient of variation of (641.43) and r-squared of  0.12. View All Fundamentals
 
Tangible Book Value Per Share  
First Reported
2010-12-31
Previous Quarter
0.71343359
Current Value
0.75
Quarterly Volatility
1.7 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cyclacel Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cyclacel Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 29.4 K, Interest Expense of 2.4 M or Selling General Administrative of 5.9 M, as well as many indicators such as Price To Sales Ratio of 5.91, Dividend Yield of 0.0929 or PTB Ratio of 3.93. Cyclacel financial statements analysis is a perfect complement when working with Cyclacel Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Cyclacel Pharmaceuticals Correlation against competitors.
For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.

Latest Cyclacel Pharmaceuticals' Tangible Book Value Per Share Growth Pattern

Below is the plot of the Tangible Book Value Per Share of Cyclacel Pharmaceuticals over the last few years. It is Cyclacel Pharmaceuticals' Tangible Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cyclacel Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Tangible Book Value Per Share10 Years Trend
Slightly volatile
   Tangible Book Value Per Share   
       Timeline  

Cyclacel Tangible Book Value Per Share Regression Statistics

Arithmetic Mean(266.38)
Coefficient Of Variation(641.43)
Mean Deviation818.73
Median83.35
Standard Deviation1,709
Sample Variance2.9M
Range7.1K
R-Value0.35
Mean Square Error2.8M
R-Squared0.12
Significance0.20
Slope134.52
Total Sum of Squares40.9M

Cyclacel Tangible Book Value Per Share History

2024 0.75
2023 0.71
2022 23.58
2021 62.62
2020 137.31
2019 215.0
2018 25.26

About Cyclacel Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Cyclacel Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Cyclacel Pharmaceuticals investors use historical funamental indicators, such as Cyclacel Pharmaceuticals's Tangible Book Value Per Share, to determine how well the company is positioned to perform in the future. Although Cyclacel Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Cyclacel Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cyclacel Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Cyclacel Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Cyclacel Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Tangible Book Value Per Share 0.71  0.75 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Cyclacel Stock

When determining whether Cyclacel Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclacel Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclacel Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclacel Pharmaceuticals Stock:
Check out the analysis of Cyclacel Pharmaceuticals Correlation against competitors.
For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(22.02)
Revenue Per Share
0.465
Return On Assets
(1.00)
Return On Equity
(4.96)
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.